Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain buoyant
Fri, 27 Jun 01:30 pm

Indian share markets pared early gains but continued to trade positive in the post-noon trading session. Sectoral indices are trading mixed with IT and pharma stocks being the major gainers whereas metal and realty stocks are among the major losers.

BSE-Sensex is up 22 points and NSE-Nifty is trading 7 points up. BSE Mid Cap is trading marginally up and BSE Small Cap index is trading up by 0.2%. The rupee is trading at 60.1 to the US dollar.

Barring MOIL Ltd, all the mining stocks are trading in the red with Coal India and NMDC among major losers. As per a leading financial daily, Coal India Ltd (CIL) has still not signed fuel supply agreements (FSA) with 12 power units for a capacity of 4,925 MW. The company has missed two deadlines, one in August 2013 and the second one in September 2013, for signing of FSA with power producers and after almost a year of Presidential directive for signing of pacts for a capacity of 78,000 MW. CIL has signed FSA's for a capacity of 73,075 MW. According to the coal and power ministry, the pacts for 4,925 MW were not signed due to date issues including extension of coal supplies beyond the period admissible under short term linkage policy, Short term linkage policy is provided to consumers who have been allocated captive coal blocks but could not be developed on time.

Pharma stocks are trading on a mixed note. While Panacea Biotech and Ranbaxy are leading the pack of gainers, Natco Pharma is trading weak. As per a leading business daily, US Food and Drug Administration (USFDA) has approved Ranbaxy's generic version of Novartis AG's blood pressure drug Diovan. This comes after the company's protracted dispute with USFDA over regulatory issue with respect to good manufacturing practices. The company will finally launch the generic version of the drug which enjoys the exclusivity period of 180 days of marketing in the US market. This launch was pending since September 2012 with US FDA and Ranbaxy will launch the drug without any delay to monetize it. Reportedly, Ranbaxy could earn about US$ 200 m from the drug sales during the 6 month exclusivity period. This approval is likely to clear the negativity surrounding the company with respect to its future launches and restoration of the three formulation facilities that are banned by USFDA currently. Ranbaxy is trading up 5.4% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.